• Patients relying on foreign pharmacies should check their next refill date now and talk with their pharmacy and prescriber about alternatives rather than waiting for a shipment to be stopped.
• For years, Americans facing eye-popping prescription prices have used an unofficial escape hatch: ordering the same or similar medicine from licensed pharmacies in Canada and other countries, often for a fraction of the U.S. price.
• That escape hatch may be about to narrow considerably.

For years, Americans facing high prescription prices have ordered medicines from licensed pharmacies in Canada and other countries, often for a fraction of the U.S. price.

That route may soon become much harder to use.

New U.S. Customs and Border Protection procedures scheduled to take effect Oct. 22 could make it more difficult for foreign pharmacies to mail prescription drugs directly to American patients, potentially disrupting a system used by millions of people, The Wall Street Journal reports.

The change does not amount to a simple government announcement banning Canadian prescriptions. Instead, international shipments containing products regulated by agencies such as the FDA will face additional customs-entry requirements. Those requirements can involve detailed electronic filings and other obligations normally handled by brokers or importers.

For pharmacies sending relatively small individual prescriptions, that extra burden could make the business impractical.

The savings can be enormous

The Journal cites a 38-year-old Dallas woman who buys Xifaxan, a prescription drug for certain gastrointestinal conditions, from a Canadian online pharmacy for about $10 a week — only a fraction of its U.S. cost.

Cases like hers explain why foreign pharmacies remain attractive despite repeated federal warnings about buying medicines outside the domestic pharmaceutical supply chain.

For some patients, ordering abroad is less about convenience than affordability.

It was never exactly legal

The customs procedures are not creating the FDA restrictions on personal drug imports. Those restrictions already exist.

The FDA says that, in most circumstances, it is illegal for an individual to import a prescription drug for personal use if the product has not been approved for sale in the United States. A drug approved in Canada can still be considered unapproved under U.S. law.

But FDA personnel may exercise enforcement discretion in limited circumstances.

Among the factors they may consider are whether the medicine treats a serious condition, whether effective treatment is unavailable domestically, whether the product poses an unreasonable health risk and whether the quantity is generally no more than a three-month supply.

Patients may also be asked to identify the U.S. physician responsible for their treatment or show that the medicine continues treatment begun overseas.

The FDA also makes clear that these guidelines do not create a legal right to import medicine.

The new customs system could make that longstanding informal accommodation much harder to use.

Washington is sending mixed signals on Canadian drugs

The situation also highlights a contradiction in U.S. prescription-drug policy.

While individual mail-order imports may become harder, federal law separately provides an official pathway specifically intended to bring lower-cost Canadian drugs into the United States.

Under Section 804 of the Federal Food, Drug and Cosmetic Act, states and Indian tribes can establish FDA-authorized programs to import certain prescription medicines from Canada.

The stated objective is to significantly reduce drug costs for American consumers without creating additional risks to public health and safety. FDA was still promoting that program in 2026 and providing states with information on developing importation plans.

The major difference is control. State programs operate through a formally approved supply chain that FDA can supervise. Individual consumers ordering medicine from overseas websites do not necessarily have the same safeguards.

FDA warns that drugs obtained outside the legitimate U.S. pharmaceutical supply chain may not offer the same assurances of quality, effectiveness, storage conditions or authenticity as medicines distributed through FDA-regulated channels.

But for patients, a drug that is technically available in the United States may be of little practical use if they cannot afford it.

Affordability Watch

The customs change illustrates a basic feature of the American prescription-drug market: the same or similar medicine can cost dramatically different amounts depending on the country where it is sold.

If foreign mail-order options disappear, patients may have to pay higher U.S. prices, seek manufacturer assistance, switch medications, appeal insurance decisions or, in the worst cases, go without treatment.

What patients should do before Oct. 22

• Check your refill schedule now. See whether your next shipment is likely to fall near or after Oct. 22.
• Ask the pharmacy what is changing. Foreign pharmacies should be able to say whether they expect to keep shipping to the United States.
• Talk with your prescriber. Ask about an FDA-approved generic, alternative drug or different formulation.
• Check your insurance formulary again. Coverage and preferred-drug lists change.
• Look for manufacturer assistance. Patient-assistance or copay programs may help, depending on eligibility.
• Don't abruptly stop an important medication. Running out of some medicines can be dangerous. Arrange an alternative with your doctor first.
• Be wary of replacement websites. Extremely low prices, no-prescription sales and unclear pharmacy addresses are warning signs.

The biggest immediate risk may not be Customs suddenly confiscating every Canadian prescription on Oct. 22. It may be that the infrastructure that allowed those prescriptions to reach American patients begins disappearing.

For patients who have built their medication budgets around foreign prices, an obscure customs rule could become a very expensive problem.